Burning Rock Biotech Limited
BNRHealthcareNASDAQDiagnostics & Research · Last scanned Sep 5, 2026
Scan Results
Daily timeframeBurning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. At a $126.5M market cap, Burning Rock Biotech Limited ranks as a micro-cap company within healthcare. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
Market Cap
$126.5M
Beta
1.39
P/E (TTM)
—
P/E (Fwd)
-20.67
EPS (TTM)
$-0.83
EPS (Fwd)
$-0.58
ROE
-10.9%
ROA
-4.5%
Cash
$446.0M
Total Debt
$50.9M
Free CF
-$19.0M
52W Change
19.0%
Annual Financials
Cash vs Debt
Where BNR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BNR finished 42.63% below its 150-day moving average ($15.95) and 47.86% below its 200-day moving average ($17.55). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BNR overbought or oversold?
At the September 3, 2026 close, BNR's RSI(14) was 48.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Burning Rock Biotech Limited holds $446.0M in cash against $50.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$19.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -10.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $563.2M (2022) to $539.6M (2025).
With cash comfortably exceeding debt, BNR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Burning Rock Biotech Limited and its sector.